Immune thrombocytopenia is an autoimmune disease where antibodies are synthesized against specific glycoproteins of platelets. The disease manifests in acute, persistent, and chronic forms. In cases of life-threatening bleeding, treatment with Revolade is necessary. While Revolade is registered in Armenia, it is quite expensive and not provided by state, making it unaffordable for many families, especially as children often need to take the medication for extended periods.

The Fund donates Revolade medication to partner hospital, through which the treatment of children is carried out.

The implemented project’s cost is between 10,000,000 to 15,000,000 drams.

The number of beneficiaries is 6 children.

The project is being implemented ongoingly.